Product Name :
CA77.1
Description:
CA77.1 is a potent, brain-penetrant and orally active chaperone-mediated autophagy (CMA) activator with favorable pharmacokinetics. CA77.1 is a derivative of AR7 (HY-101106) and can increase the expression of the lysosomal receptor LAMP2A in lysosomes. CA77.1 improves behavior and neuropathology in PS19 mice model and can be used for alzheimer’s disease research.
CAS:
2412270-22-3
Molecular Weight:
297.74
Formula:
C16H12ClN3O
Chemical Name:
N-[4-(6-chloroquinoxalin-2-yl)phenyl]acetamide
Smiles :
CC(=O)NC1C=CC(=CC=1)C1=CN=C2C=C(Cl)C=CC2=N1
InChiKey:
ZQXMPDVGBWOTBY-UHFFFAOYSA-N
InChi :
InChI=1S/C16H12ClN3O/c1-10(21)19-13-5-2-11(3-6-13)16-9-18-15-8-12(17)4-7-14(15)20-16/h2-9H,1H3,(H,19,21)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
CA77.1 is a potent, brain-penetrant and orally active chaperone-mediated autophagy (CMA) activator with favorable pharmacokinetics. CA77.1 is a derivative of AR7 (HY-101106) and can increase the expression of the lysosomal receptor LAMP2A in lysosomes. CA77.1 improves behavior and neuropathology in PS19 mice model and can be used for alzheimer’s disease research.|Product information|CAS Number: 2412270-22-3|Molecular Weight: 297.{{Florfenicol} site|{Florfenicol} Antibiotic|{Florfenicol} Biological Activity|{Florfenicol} In Vivo|{Florfenicol} manufacturer|{Florfenicol} Epigenetic Reader Domain} 74|Formula: C16H12ClN3O|Chemical Name: N-[4-(6-chloroquinoxalin-2-yl)phenyl]acetamide|Smiles: CC(=O)NC1C=CC(=CC=1)C1=CN=C2C=C(Cl)C=CC2=N1|InChiKey: ZQXMPDVGBWOTBY-UHFFFAOYSA-N|InChi: InChI=1S/C16H12ClN3O/c1-10(21)19-13-5-2-11(3-6-13)16-9-18-15-8-12(17)4-7-14(15)20-16/h2-9H,1H3,(H,19,21)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 5 mg/mL (16.{{Agarose} site|{Agarose} TGF-beta/Smad|{Agarose} Technical Information|{Agarose} Formula|{Agarose} custom synthesis} 79 mM; ultrasonic and warming and heat to 60°C).PMID:24189672 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|CA77.1 (0-30 μM; 16 hours) activates CMA in a dose-and time-dependent manner to NIH 3T3 cells stably expressing the KFERQ-PS-Dendra reporter. The CMA activity is quantified as the average of fluorescent puncta per cell. CA77.1 (20 μM; 6 hours) does not alter on LC3-II expression, and does not effects autophagic flux in NIH 3T3 cells.|In Vivo:|CA77.1 (oral gavage; 10 mg/kg;single dose) demonstrates brain penetrance with favorable pharmacokinetics. The Cmax, AUClast, Tmax and T1/2 are 3534 ng/g, 8338 h*ng/g, 1 hour and 1.89 hour, respectively. CA77.1 (oral gavage; 30 mg/kg; 6 months) normalizes the previously described locomotor hyperactivity of PS19 mice to control levels. And it reduces the levels and number of neurons containing pathogenic tau conformations in the hippocampus, amygdala, and piriform cortex. And the higher number of microglial cells and presence of large Iba1-positive cells with rod-like dystrophic morphology in vehicle-treated PS19 mice are reduced upon CA77.1 treatment.|Products are for research use only. Not for human use.|
